[go: up one dir, main page]

CO2019007839A2 - Composiciones y métodos para inhibir la acción de la arginasa - Google Patents

Composiciones y métodos para inhibir la acción de la arginasa

Info

Publication number
CO2019007839A2
CO2019007839A2 CONC2019/0007839A CO2019007839A CO2019007839A2 CO 2019007839 A2 CO2019007839 A2 CO 2019007839A2 CO 2019007839 A CO2019007839 A CO 2019007839A CO 2019007839 A2 CO2019007839 A2 CO 2019007839A2
Authority
CO
Colombia
Prior art keywords
arginase
methods
compositions
inhibiting
action
Prior art date
Application number
CONC2019/0007839A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Lijing Chen
Roland J Billedeau
Timothy F Stanton
Zandt Michael Van
Darren Whitehouse
Gunnar E Jagdmann Jr
Lene Raunkjaer Petersen
Francesco Parlati
Matthew I Gross
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019007839(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CO2019007839A2 publication Critical patent/CO2019007839A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La descripción consiste en una clase novedosa de compuestos que muestran actividad inhibitoria de la arginasa, y composiciones farmaceúticas que incluyen los compuestos de la descripción. En la presente también se ofrecen los métodos de tratamiento contra el cáncer con los inhibidores de la arginasa de la descripción.
CONC2019/0007839A 2016-12-22 2019-07-22 Composiciones y métodos para inhibir la acción de la arginasa CO2019007839A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438092P 2016-12-22 2016-12-22
US201662439614P 2016-12-28 2016-12-28
PCT/US2017/068307 WO2018119440A1 (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
CO2019007839A2 true CO2019007839A2 (es) 2019-10-21

Family

ID=60972528

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007839A CO2019007839A2 (es) 2016-12-22 2019-07-22 Composiciones y métodos para inhibir la acción de la arginasa

Country Status (33)

Country Link
US (4) US10287303B2 (es)
EP (2) EP3559009B1 (es)
JP (2) JP7018949B2 (es)
KR (1) KR102579849B1 (es)
CN (2) CN110382508B (es)
AU (2) AU2017382405B2 (es)
BR (1) BR112019012589B1 (es)
CA (1) CA3046987A1 (es)
CL (1) CL2019001711A1 (es)
CO (1) CO2019007839A2 (es)
CR (1) CR20190339A (es)
CY (1) CY1124483T1 (es)
DK (2) DK3559009T3 (es)
EC (1) ECSP19045511A (es)
ES (2) ES2881395T3 (es)
HR (1) HRP20210848T1 (es)
HU (1) HUE054272T2 (es)
IL (2) IL292677A (es)
LT (1) LT3559009T (es)
MD (1) MD3559009T2 (es)
MX (2) MX378460B (es)
MY (1) MY197478A (es)
NZ (1) NZ754364A (es)
PE (1) PE20191541A1 (es)
PH (1) PH12019501396A1 (es)
PL (1) PL3559009T3 (es)
PT (1) PT3559009T (es)
RS (1) RS61996B1 (es)
SG (2) SG10201911243WA (es)
SI (1) SI3559009T1 (es)
SM (1) SMT202100573T1 (es)
TW (1) TWI818902B (es)
WO (1) WO2018119440A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
EP3828171A1 (en) 2015-12-22 2021-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
AU2017281285C1 (en) 2016-06-20 2022-05-12 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10201911243WA (en) 2016-12-22 2020-02-27 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
PE20200005A1 (es) * 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
CN108322295B (zh) 2017-01-17 2021-12-24 维沃移动通信有限公司 一种边带信息的发送方法、接收方法、发送端和接收端
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US10851099B2 (en) 2018-03-29 2020-12-01 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
KR20250067967A (ko) 2018-03-30 2025-05-15 인사이트 코포레이션 면역조절제로서 복소환형 화합물
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
EA202190532A1 (ru) * 2018-08-22 2021-07-08 Астразенека Аб Ингибиторы аргиназы и способы их применения
EP3897622B1 (en) * 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
IL285108B2 (en) * 2019-02-08 2024-10-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
TWI879811B (zh) 2019-09-30 2025-04-11 美商英塞特公司 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
PH12022551136A1 (en) 2019-11-11 2023-10-09 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
MX2023000056A (es) 2020-07-02 2023-04-12 Incyte Corp Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
US20220041630A1 (en) 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
CN116670114A (zh) 2020-11-06 2023-08-29 因赛特公司 用于制备pd-1/pd-l1抑制剂以及其盐和结晶形式的方法
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN112387262B (zh) * 2020-11-10 2021-12-07 泰州学院 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
CA3246102A1 (en) * 2022-01-07 2023-07-13 The Trustees Of Columbia University In The City Of New York Inhibition of kynurenine synthesis and/or signaling for the treatment of leukemia and myelodysplasia
CA3254582A1 (en) 2022-03-17 2023-09-21 Incyte Corporation TRICYCLIC UREA COMPOUNDS AS JAK2 INHIBITORS V617F
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
TW202440086A (zh) 2023-03-13 2024-10-16 美商英塞特公司 作為激酶抑制劑之雙環脲

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
WO1999019295A1 (en) 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1294770B1 (en) 2000-05-10 2011-12-07 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
US20080182882A1 (en) 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CA2669300A1 (en) 2006-11-21 2008-05-29 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
WO2009008415A1 (ja) 2007-07-12 2009-01-15 Sanyo Denki Co., Ltd. 二重反転式軸流送風機
CN103191129A (zh) 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
WO2011116299A2 (en) 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
CA2722159C (en) 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
HRP20141094T1 (hr) 2008-07-08 2015-01-16 Incyte Corporation 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
ES2729474T3 (es) 2009-01-26 2019-11-04 Univ Pennsylvania Inhibidores de la arginasa y métodos de uso
WO2011082245A2 (en) 2009-12-31 2011-07-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN104876955B (zh) 2010-04-22 2018-11-23 马尔斯公司 精氨酸酶抑制剂及其治疗应用
RS55010B1 (sr) 2010-04-24 2016-11-30 Viamet Pharmaceuticals Inc Jedinjenja koja inhibiraju metaloencime
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
AU2011295440B2 (en) 2010-08-27 2015-06-11 Merck Patent Gmbh Triazolopyrazine derivatives
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
JP5921560B2 (ja) 2010-10-28 2016-05-24 イノクリン ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害化合物
EA024197B1 (ru) 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CA2820718A1 (en) 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012091757A1 (en) 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
NO2694640T3 (es) 2011-04-15 2018-03-17
IN2014MN00093A (es) 2011-06-19 2015-06-19 Viamet Pharmaceuticals Inc
US8796001B2 (en) 2011-06-19 2014-08-05 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012177728A1 (en) 2011-06-23 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9150527B2 (en) 2011-08-30 2015-10-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US9957271B2 (en) * 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
SI2788343T1 (sl) 2011-12-11 2019-09-30 Viamet Pharmaceuticals (NC), Inc. Spojine inhibitorja metaloencimov
ES2774267T3 (es) 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
EP2807161B1 (en) 2012-01-28 2017-10-04 Merck Patent GmbH Triazolo[4,5-d]pyrimidine derivatives
AU2013224421B2 (en) 2012-02-21 2017-03-02 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
AU2012370450B2 (en) 2012-02-21 2017-02-02 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
CN104159901B (zh) 2012-03-07 2016-10-26 默克专利股份公司 三唑并吡嗪衍生物
CN104540836B (zh) 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
JP6374384B2 (ja) 2012-08-07 2018-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
EP2894981B1 (en) 2012-09-12 2019-12-04 Dow AgroSciences LLC Metalloenzyme inhibitor compounds
AU2013337663A1 (en) 2012-11-02 2015-06-11 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
WO2014117090A1 (en) 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
AU2014224975B2 (en) 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
EA201591610A1 (ru) 2013-03-14 2015-12-30 Курадев Фарма Прайвит Лтд. Ингибиторы кинуренинового пути
SG10201707545XA (en) 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
AU2014235816B2 (en) 2013-03-15 2018-05-17 Bristol-Myers Squibb Company IDO inhibitors
SI2970155T1 (en) 2013-03-15 2018-06-29 Bristol-Myers Squibb Company INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO)
ES2637721T3 (es) 2013-05-06 2017-10-16 Merck Patent Gmbh Macrociclos como inhibidores de quinasa
EP3004067A4 (en) 2013-05-28 2016-10-12 Viamet Pharmaceuticals Inc FUNGICIDE COMPOSITIONS
EA029126B1 (ru) 2013-07-01 2018-02-28 Бристол-Майерс Сквибб Компани Ингибиторы ido
JP6478991B2 (ja) 2013-07-11 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
WO2015017402A1 (en) 2013-07-29 2015-02-05 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of biofilm infections
JP6371851B2 (ja) 2013-08-27 2018-08-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
CN105848680A (zh) 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
JP6461953B2 (ja) 2013-11-08 2019-01-30 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ インドールアミン２，３−ジオキシゲナーゼ阻害剤の合成のためのプロセス
ES2856330T3 (es) 2014-02-04 2021-09-27 Incyte Corp Combinación de un antagonista de PD-1 y un inhibidor de IDO1 para el tratamiento del cáncer
JP2017513848A (ja) 2014-04-15 2017-06-01 ダウ アグロサイエンシィズ エルエルシー 殺真菌剤としての金属酵素阻害剤化合物
KR20160145640A (ko) 2014-04-15 2016-12-20 다우 아그로사이언시즈 엘엘씨 살진균제로서의 금속효소 억제제 화합물
US10987322B2 (en) 2014-06-06 2021-04-27 Flexus Biosciences, Inc. Immunoregulatory agents
TW201619133A (zh) 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
WO2016037026A1 (en) 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
GB201418300D0 (en) 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
WO2016153078A1 (en) 2015-03-20 2016-09-29 Opiyo Sammy Oyoo Use of suramin and arginase inhibitors in malignant neoplasia
SG11201708097SA (en) 2015-04-03 2017-10-30 Bristol Myers Squibb Co Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
WO2016181349A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
MA42269A (fr) 2015-06-23 2018-05-02 Calithera Biosciences Inc Compositions et procédés d'inhibition de l'activité de l'arginase
EA038276B1 (ru) 2015-10-30 2021-08-04 Калитера Байосайенсиз, Инк. (3r,4s)-3-амино-1-((s)-2-аминопропаноил)-4-(3-боронопропил)пирролидин-3-карбоновая кислота, композиции на ее основе и ее применение для лечения рака
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
SG10201911243WA (en) 2016-12-22 2020-02-27 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
MA48626A (fr) 2017-05-12 2020-03-18 Calithera Biosciences Inc Procédé de préparation de (3r,4s)-3-acétamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

Also Published As

Publication number Publication date
TW201828948A (zh) 2018-08-16
LT3559009T (lt) 2021-06-25
AU2017382405B2 (en) 2021-12-16
PE20191541A1 (es) 2019-10-23
BR112019012589B1 (pt) 2022-11-29
CN110382508B (zh) 2022-08-02
KR102579849B1 (ko) 2023-09-18
US20190330244A1 (en) 2019-10-31
PL3559009T3 (pl) 2021-10-25
EP3842442B1 (en) 2023-11-01
US20210261573A1 (en) 2021-08-26
CA3046987A1 (en) 2018-06-28
TWI818902B (zh) 2023-10-21
IL267532A (en) 2019-08-29
US10597411B2 (en) 2020-03-24
BR112019012589A2 (pt) 2019-11-19
PH12019501396A1 (en) 2019-12-02
NZ754364A (en) 2023-04-28
ES2970715T3 (es) 2024-05-30
CR20190339A (es) 2020-01-10
WO2018119440A1 (en) 2018-06-28
KR20190119579A (ko) 2019-10-22
US20200339607A1 (en) 2020-10-29
MX2019007471A (es) 2019-11-05
JP7018949B2 (ja) 2022-02-14
EP3842442A1 (en) 2021-06-30
SMT202100573T1 (it) 2021-11-12
JP2020514271A (ja) 2020-05-21
DK3842442T3 (da) 2024-02-05
MD3559009T2 (ro) 2021-07-31
SG10201911243WA (en) 2020-02-27
MX2020013649A (es) 2021-02-26
AU2017382405A1 (en) 2019-06-27
AU2022201072A1 (en) 2022-03-10
CN114989205A (zh) 2022-09-02
IL267532B (en) 2022-06-01
EP3559009B1 (en) 2021-04-07
HRP20210848T1 (hr) 2021-07-09
RS61996B1 (sr) 2021-07-30
CL2019001711A1 (es) 2020-01-17
DK3559009T3 (da) 2021-05-03
CN110382508A (zh) 2019-10-25
US12054501B2 (en) 2024-08-06
US20180222926A1 (en) 2018-08-09
HUE054272T2 (hu) 2021-09-28
ECSP19045511A (es) 2019-10-31
JP2022066199A (ja) 2022-04-28
MX378460B (es) 2025-03-10
EP3559009A1 (en) 2019-10-30
IL292677A (en) 2022-07-01
US10287303B2 (en) 2019-05-14
SG10201911240PA (en) 2020-02-27
PT3559009T (pt) 2021-05-04
MY197478A (en) 2023-06-19
ES2881395T3 (es) 2021-11-29
SI3559009T1 (sl) 2021-08-31
US11021495B2 (en) 2021-06-01
CY1124483T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CL2020002082A1 (es) Inhibidores pd-1/pd-l1.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
MX2018013593A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы